Renovaro Biosciences
Cash Flow

Last updated:

Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Renovaro Biosciences generated cash of -$10,971,430, which is more than the previous year. Cash used in financing activities reached the amount of $10,517,455 last year. Net change in cash is therefore -$1,654,013.

Cash Flow

Renovaro Biosciences Inc. (NASDAQ:RENB): Cash Flow
2016 -1.47M 0 0
2018 -4.33M -575.73K 16.71M
2020 -10.45M -184.46K 7.2M
2023 -11.77M -29.77K 4.51M
2024 -10.97M -1.26M 10.51M

RENB Cash Flow Statement (2015 – 2023)

2023 2022 2019 2017 2015
Cash at beginning of period
1.87M9.17M12.28M3.94M1.49M
Operating activities
Net income
-80.65M-39.68M-11.41M-6.31M-1.73M
Adjustments to reconcile net income to cash generated by operating activities:
Depreciation and amortization
121.85K113.49K366.26K18.48K27.39K
Stock-based compensation expense
4.67M3.53M1.02M00
Deferred income tax benefit 4.67M3.53M1.02M00
Changes in operating assets and liabilities:
Accounts receivable, net
04618.81K108.00K-263.29K
Inventories
00000
Accounts payable
4.05M3.89M59.31K119.57K574.97K
Cash generated by operating activities
-10.97M-11.77M-10.45M-4.33M-1.47M
Investing activities
Purchases Of Investments
00000
Investments In Property Plant And Equipment
-70.43K-29.77K-184.46K-30K0
Acquisitions Net
65.85K00-294.93K0
Cash generated by investing activities
-1.26M-29.77K-184.46K-575.73K0
Financing activities
Common Stock Issued
3M4.01M1M16.71M0
Payments for dividends
00000
Repurchases of common stock
00000
Repayments of term debt
7.17M-1.12M6.2M00
Cash used in financing activities
10.51M4.51M7.2M16.71M0
Net Change In Cash
-1.65M-7.29M-3.58M11.65M-1.47M
Cash at end of period
220.46K1.87M8.69M15.60M23.36K
Data source